A world-wide provider of on-demand DNA printing's recent announcement that it had secured $200 million of new capital is only the beginning, the company's CEO said in a recent news release.
The new capital, raised through Series C financing, will be used to fund DNA Script's SYNTAX Platform and to launch DNA Script's Enzymatic DNA Synthesis (EDS) technology, according to the company's news release.
"We are thrilled to partner with this world-class group of investors, including new participants Baillie Gifford and T. Rowe Price, who collectively share our vision to increase access to oligo manufacturing to accelerate the bio-revolution," DNA Script Co-founder and CEO Thomas Ybert said in the Jan. 4 news release. "SYNTAX is the first step toward creating a new paradigm for DNA and RNA synthesis. With the support of our investors, we look forward to continuing to advance this new paradigm to solve some of our largest challenges and advance human health."
The SYNTAX Platform is DNA Script's first commercial product, powered by its proprietary EDS technology, that helps scientists rapidly print synthetic nucleic acids for genomics and molecular biology applications. On-demand printing makes it possible for labs to iterate for more rapidly than they could working more traditionally with third-party service providers.
The new capital came through accounts and funds advised by T. Rowe Price Associates and Baillie Gifford, which participated in the second tranche of the Series C financing, in addition to HealthCor Management, eureKARE and Irving Investors. Coatue Management, Catalio Capital Management, Fidelity Management & Research Company LLC, Columbia Threadneedle Investments, Casdin Capital and other investors participated in the first closing, DNA Script announced in October.
DNA Script was founded in 2014 as a life sciences technology company to develop new, faster, more powerful and versatile ways to design and manufacture nucleic acids. The company, headquartered in California and France, has taken in about $315 million since its founding.
Also recently, DNA Script announced that Ybert was to present about the company's growth and vision during the 40th Annual J.P. Morgan Healthcare Conference, held virtually on Jan. 10.